CYLD expression is downregulated through a range of mechanisms in melanoma (Massoumi et al., 2009), breast cancer (Hayashi et al., 2014), haematologic malignancies (Espinosa et al., 2010; Walker et al., 2015), colon cancer, hepatocellular cancer (Hellerbrand et al., 2007), neuroblastoma (Kobayashi et al., 2015) and basal cell prostate cancer (Low et al., 2023) (Table 2). The gene discussed is CYLD; the disease is melanoma.